Wide Ranks

ITOS

iTeos Therapeutics, Inc.

8.54

Top Statistics
Market Cap 311 M Forward PE -2.00 Revenue Growth 0.00 %
Current Ratio 14.80 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.18 Enterprise / Revenue -4.89 Price To Sales Trailing12 Months 8.91
Profitability
Profit Margins 0.00 % Operating Margins -417.41 %
Balance Sheet
Total Cash 488 M Total Cash Per Share 13.38 Total Debt 5 M
Total Debt To Equity 0.8750 Current Ratio 14.80 Book Value Per Share 17.29
All Measures
Short Ratio 338.00 % Message Board Id finmb_663087242 Shares Short Prior Month 3 M
Return On Equity -0.1972 City Watertown Uuid fc26d83f-6905-3b2f-9b33-72f7f481fa2a
Previous Close 8.19 First Trade Date Epoch Utc 1 B Book Value 17.29
Beta 1.39 Total Debt 5 M Volume 541329
Price To Book 0.4938 Fifty Two Week Low 7.54 Total Cash Per Share 13.38
Total Revenue 35 M Shares Short Previous Month Date 1 B Target Median Price 33.50
Max Age 86400 Recommendation Mean 1.50 Sand P52 Week Change 0.3133
Operating Margins -417.41 % Target Mean Price 34.50 Net Income To Common -121253000
Short Percent Of Float 0.1132 Implied Shares Outstanding 36 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 594520 Average Volume10days 594520
Total Cash 488 M Next Fiscal Year End 1 B Revenue Per Share 0.9060
Held Percent Insiders 0.0071 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 8.19 Target Low Price 22.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.23 Open 8.26
Free Cashflow -90691752 State MA Dividend Yield 0.00 %
Return On Assets -0.1304 Time Zone Short Name EST Trailing Eps -3.14
Day Low 8.21 Address1 321 Arsenal Street Shares Outstanding 36 M
Price Hint 2 Target High Price 47.00 Website https://www.iteostherapeutics.com
52 Week Change -0.0876 Average Volume 716223 Forward Eps -5.85
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1443.80 %
Is_sp_500 False Regular Market Day High 8.56 Profit Margins 0.00 %
Debt To Equity 0.8750 Fifty Two Week High 18.75 Day High 8.56
Shares Short 2 M Regular Market Open 8.26 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -4.89 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0605 Operating Cashflow -117443000 Currency USD
Time Zone Full Name America/New_York Market Cap 311 M Is_nasdaq_100 False
Zip 02472 Quote Type EQUITY Industry Biotechnology
Long Name iTeos Therapeutics, Inc. Regular Market Day Low 8.21 Held Percent Institutions 1.05
Current Price 8.54 Address2 Suite 301 Building 312 Enterprise To Ebitda 1.18
Financial Currency USD Current Ratio 14.80 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 23 M Two Hundred Day Average 13.01 Enterprise Value -171182336
Price To Sales Trailing12 Months 8.91 Forward PE -2.00 Regular Market Volume 541329
Ebitda -144951008 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer.

The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials.

Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.